SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 PM ET and the RBC Capital Markets 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 9:45 AM ET.
The live and archived webcast of the presentation will be accessible in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com
London, United Kingdom--(Newsfile Corp. - April 12, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or…
MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2024 / LIVIN Foundation, a Minnesota-based non-profit and…
- Synuclein-One Study plenary session on Monday, April 15 at 9:15 a.m. MT will report…
Red Light Holland Advances Psilocybin Research Collaboration with CCrest Labs and PharmAla BiotechLargest Shipment of…
Toronto, Ontario--(Newsfile Corp. - April 12, 2024) - Glow LifeTech Corp. (CSE: GLOW) (OTC Pink:…
Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…